Non-Metastatic Castration Resistant Prostate Cancer Treatment Market Size

  • Report ID: 2884
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Non-Metastatic Castration Resistant Prostate Cancer Treatment Market Size

Non-Metastatic Castration Resistant Prostate Cancer (nmCRPC) Treatment Market size was valued at USD 7.68 billion in 2024 and is likely to cross USD 14.13 billion by 2037, expanding at more than 4.8% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of non-metastatic castration resistant prostate cancer treatment is estimated at USD 8.28 billion.

The growth of the market can be attributed to the increasing geriatric population and the rising prevalence of non-metastatic castration-resistant prostate cancer amongst individuals on a global level. People above 50 have a higher chance to be diagnosed with nmCRPC, therefore, the surge in the geriatric population is anticipated to be one of the major growth factors of the market. According to the data collected by the National Cancer Institute of the U.S. Department of Health and Human Services, in 2020, the estimated new cases and the number of deaths from prostate cancer in the U.S. were 191,930 and 33,330, respectively.

In addition to these, global non-metastatic castration resistant prostate cancer (NMcrpc) market trends such as Extensive research associated with cancer treatment in western countries, along with the growing investment in the development of advanced therapies are expected to fuel the progress of the market during the forecast period. People nowadays are more aware of early diagnosis of cancer owing to the surge in awareness and launch of the various government program to promote the treatment of cancer. For instance, in India government programs such as Health Minister’s Cancer Patient Fund, National Health Protection Scheme, and others are observed to be quite beneficial to get cancer treatment. Hence, all these factors are anticipated to influence the market growth over the forecast period.


Get more information on this report: Request Free Sample PDF


Author Credits:  Radhika Pawar


  • Report ID: 2884
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of non-metastatic castration resistant prostate cancer treatment is estimated at USD 8.28 billion.

The non-metastatic castration resistant prostate cancer treatment market size was valued at USD 7.68 billion in 2024 and is likely to cross USD 14.13 billion by 2037, expanding at more than 4.8% CAGR during the forecast period i.e., between 2025-2037. Growing prevalence of prostate cancer and growth in the investment and R&D activities in oncology will boost the market growth.

North America industry is anticipated to dominate majority revenue share of 30% by 2037, propelled by increasing awareness about nmCRPC and the need to develop innovative cancer treatment solutions in the region.

The major players in the market are Pfizer Inc., Astellas Pharma Inc., Clovis Oncology, Inc., Johnson & Johnson Health Care Systems Inc., Bayer AG, Orion Corporation, Merck & Co., Inc., Novartis AG, AstraZeneca PLC
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample